FEBS Press is pleased to welcome its fourth journal, Molecular Oncology, to this platform. Molecular Oncology will become fully Open Access from 2017 and authors wishing to submit a paper, can do so here. The publication of high-quality journals by scientists for scientists is one the core objectives of The Federation of European Biochemical Societies (FEBS), with the revenue raised supporting fellowships, courses, congresses and other activities.
The FEBS Journal
The FEBS Journal Special Issue on CRISPR/Cas9 Gene Editing is out! Nine specially commissioned reviews from experts in the field cover topics from the initial discovery of CRISPR in bacteria, to the available tools and multiple applications of this powerful technology. We are grateful to our authors and referees for their contributions to this Special Issue, and hope you enjoy reading these pieces as much as we have!
Nuria Montserrat and colleagues (2016), The FEBS Journal
Recent advances in stem cell culturing and tissue engineering hold great promise for organ regeneration. In this State-of-the-Art Review, Montserrat and colleagues review current protocols for kidney cell regeneration from patient-derived induced pluripotent stem cells and highlight future directions for the development of functional kindey grafts.
The activation of μ-opioid receptor potentiates LPS-induced NF-kB promoting an inflammatory phenotype in microglia
Stefania Merighi and colleagues, FEBS Letters
Neuroinflammation has been implicated in the development of tolerance to opioids. Here, Merighi and colleagues investigate how the opioid morphine affects lipopolysaccharide (LPS)-induced activation of nuclear factor-κB (NF-κΒ) in primary microglia. Morphine activated NF-κΒ and pro-inflammatory cytokine production through both μ-opioid receptor and the innate immune receptor TLR4 in a protein kinase Cε (PKCε)-dependent manner. The authors suggest PKCε targeting as a potential strategy against opioid tolerance.
Nagahama, Masami and colleagues, FEBS Letters
The TRAMP complex targets aberrant RNAs for degradation by the exosome. In this study, the authors investigate the interactions between human TRAMP-like proteins and the nuclear exosome to reveal a novel role for the RRP6 catalytic subunit of the exosome in this process. Furthermore, the study provides evidence for the involvement of human TRAMP-like proteins in nuclear exosome-mediated turnover of the by-products of pre-ribosomal RNA processing.
AC-1001 H3 CDR peptide induces apoptosis and signs of autophagy in vitro and exhibits antimetastatic activity in a syngeneic melanoma model
Luiz Travassos and colleagues, FEBS Open Bio
The use of naturally derived peptides is an emerging strategy for the development of anti-cancer therapeutics. Luiz Travassos and colleagues employed this tactic in the design of an antibody derived peptide for the potential treatment of melanoma. Cytotoxic effects were observed in tumour cell lines and anti-metastatic effects seen in vivo.
FEBS Press News
News from FEBS
Congratulations to the winners of the FEBS Anniversary Prizes 2016!
The awards recognize the achievements of young researchers invited to speak at a FEBS Congress...
Nominations open for the 2018 Biochemical Society Awards
There are three new awards this year...
The FEBS 2016 Congress is cancelled
The FEBS Executive Committee are very sorry to announce that the FEBS Congress in Kuşadasi from 3rd to 8th September is cancelled...
The July 2016 issue of FEBS News is out!
From fellowships to events to journals – enjoy a snapshot of current FEBS activities ...